Vivimed Labs Ltd is hoping to cash in on the global market potential for formulations post its acquisition of Spain-based active pharmaceutical ingredients maker, Uquifa, early this month. The Hyderabad-based company would go for backward integration by shifting Uquifa's pharma ingredients production to India.
Another plant to make finished dosages is also being set up exclusively for regulated markets at Choutuppal near here. “The combined investment in these plants is about Rs 190 crore. All of them should begin production by end of next financial year. The pharma business was moving towards finished dosages for sustainable growth.
The turnover of the company would zoom to Rs 1,000 crore by end of next financial year with an equal share of specialty chemicals and pharmaceuticals in revenue. The operations of Uquifa which are now in the UK and Spain would be rationalised by bringing everything to Spain.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: